Filing summary
Registrant: Celsion Corporation, a clinical-stage oncology drug developer. The request metadata names Imunon, Inc., but the supplied 10-Q is Celsion’s filing for the quarter ended June 30, 2011, filed August 9, 2011.
Business context and reporting period
Celsion was developing ThermoDox, a heat-activated liposomal doxorubicin, principally in the Phase III HEAT study for primary liver cancer and a Phase I/II study for recurrent chest-wall breast cancer. The financial statements cover the three and six months ended June 30, 2011, compared with the same 2010 periods.
Financial performance and position
| Metric | Q2 2011 | First half 2011 |
|---|---|---|
| Revenue | None | $2.0 million licensing revenue |
| Research and development expense | $4.96 million | $9.31 million |
| General and administrative expense | $1.28 million | $2.50 million |
| Operating loss | $6.25 million | $9.81 million |
| Net loss | $6.94 million | $10.71 million |
| Net loss per share, basic and diluted | $0.42 | $0.72 |
| Cash used in operating activities | Not separately stated | $11.40 million |
At June 30, cash and cash equivalents were $5.38 million and short-term investments were $0.13 million. Current assets of $6.21 million exceeded current liabilities of $5.14 million, producing working capital of approximately $1.07 million. Total liabilities were $6.40 million; the equipment note payable was $120,152, all current. The company reported an accumulated deficit of $111.67 million. As a development-stage business with no product sales, conventional operating margin comparisons are not meaningful.
Changes versus comparable periods
- Q2 operating expenses rose 39.9% to $6.25 million, and net loss increased to $6.94 million from $2.63 million in Q2 2010. Higher Phase III clinical-trial costs were the main operating driver.
- For the first half, operating expenses rose 30.7% to $11.81 million. R&D increased 38.9%, largely from greater HEAT enrollment activity and manufacturing development.
- First-half licensing revenue of $2.0 million came from Yakult under an amended ThermoDox agreement; there was no comparable revenue in 2010. In exchange for accelerated payments of up to $4.0 million, future Japanese approval milestone payments were reduced by approximately 40%.
- First-half interest and dividend expense increased to $481,087, primarily associated with the January preferred-stock financing. A noncash warrant-valuation charge of $417,860 also reduced results, versus a noncash gain of $258,925 in first-half 2010.
- Working capital improved from a $4.77 million deficit at December 31, 2010, reflecting financing proceeds and the licensing payment. Common shares outstanding increased materially during the first half through conversions and equity issuance.
Liquidity, outlook, risks, and notable events
- First-half financing provided $15.52 million, including net proceeds from preferred stock, the June common-stock offering, and CEFF draws. The CEFF capacity was exhausted during Q2.
- After quarter-end, July equity offerings generated approximately $25 million gross and approximately $23 million net, according to management. The offerings included common shares and warrants and triggered mandatory conversion of the remaining preferred stock into common stock, expected on or about August 5, 2011.
- Management said the post-offering cash position was expected to fund operations for the next twelve months and beyond, while also stating that additional capital would be required in 2012 to advance development, manufacturing, and commercialization. Further financing may dilute shareholders or require concessions on product or technology rights.
- On July 11, the HEAT study’s monitoring committee recommended continued enrollment outside Japan while Japan enrollment remained on hold pending guidance from Japan’s regulator. On August 3, Celsion announced that enrollment had reached 600 patients; it expected the second interim-analysis trigger, 190 progression-free-survival events, in Q3 2011 and the interim analysis in Q4, but timing and outcome were uncertain.
- Key risks include clinical-trial safety, efficacy and timing; the need for future financing; regulatory approval and commercialization uncertainty; and possible Nasdaq delisting if market value again falls below the $35 million continued-listing threshold. Celsion said it had regained compliance in May 2011.
- A planned move of corporate functions from Maryland to New Jersey was subject to receipt of a state employment grant. The company reported no legal proceedings and no material change in internal control over financial reporting; management concluded disclosure controls were effective at a reasonable-assurance level.
Most important facts for investors to verify
- Current cash, quarterly cash burn, and whether management’s stated runway remains adequate after the July offerings.
- HEAT study status, the Japan enrollment restriction, the interim-analysis trigger and timing, and any subsequent clinical or regulatory updates.
- The actual conversion of preferred shares, resulting share count, warrant dilution, and net proceeds from the July financings.
- The terms and implications of the Yakult milestone reduction and whether the conditional second $2 million payment was received.
- Nasdaq continued-listing compliance and whether the New Jersey relocation grant and lease conditions were satisfied.